Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...
AdvanCell is developing therapies to treat cancers including: prostate, skin, pancreatic, breast, bladder, colorectal, kidney ...
Eli Lilly inked two collaborations on Monday, one focused on cardiometabolic diseases with South Korea’s OliX Pharmaceuticals ...
Announced on February 10, Eli Lilly is expanding its collaboration with AdvanCell to advance targeted alpha therapies for ...
AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha therapies, today announced an expansion to the scope and breadth of its strategic collaboration with Eli Lilly ...
Brisbane-based AdvanCell raised $178 million in one of the biggest funding rounds of 2025 so far. It's good news for an ...
AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha therapies, is expanding the scope and ...
Australian clinical-stage radiopharmaceutical company AdvanCell has announced an expansion to the scope and breadth of its ...
Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for ...
BRISBANE, Australia & INDIANAPOLIS--(BUSINESS WIRE)--AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha therapies, today announced an expansion to the scope and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback